DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022" report to their offering.
The double barreled antibodies market is anticipated to reach US$ 604.9 Million by 2022
In this report, there is in-depth market analysis of BLINCYTO and Removab. The double barreled antibodies market is still in its infancy. With the European Medicines Agency approval of Removab in 2009, a great deal of interest has been generated in the bi-specific antibody market. The bi-specific antibodies pipeline is rich and diverse, and has drugs being developed for both oncological and non-oncological indications. These drugs are based on various technological platforms developed by Roche, Amgen, AbbVie, Ablynx, Affimed, and MacroGenics amongst others. The antibody platforms are based on the concepts of chemical cross-linking, hybridomas, as well as recombinant techniques.
During the course of the research, the researcher found bi-specific antibodies currently in different stages of clinical development. Most of these are industry sponsored, and around 2-3 of the bi-specific antibody drugs amongst them are expected to be launched by the end of this decade. In addition to the clinical pipeline, over 30 molecules have been identified which are currently in preclinical/discovery phase.
Technological advancements, particularly in the bi-specific antibodies purification will ensure the development of products with improved safety, potency, and efficacy profile. As more products move from pipeline to the market, an increase in the investment in this bi-specific antibodies development is expected from various quarters in coming years. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry's growth.
In the end, the report enlists some of the key players in the double barreled antibodies market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Double Barreled Antibodies - An Introduction
4. Double Barreled Antibodies Market Outlook to 2022
5. Double Barreled Antibodies Pipeline Analysis
6. Market Dynamics
7. Current Status of Potential Double Barreled Antibodies in Pipeline
8. Trends and Developments
9. Strategic Collaborations in the Double Barreled Antibody Industry
10. Competitive Assessment
- AbbVie Inc.
- Amgen Inc.
- Aptevo Therapeutics Inc.
- F. Hoffman La Roche Ltd.
- Fresenius SE & Co. KGaA
- Glenmark Pharmaceuticals Limited
- Ligand Pharmaceuticals, Inc.
- MacroGenics, Inc.
- Merus N.V.
- OncoMed Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- Xencor, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/3t28ln/global_double